Minimally invasive surgery and cancer: controversies part 1
Open Access
- 2 July 2009
- journal article
- review article
- Published by Springer Nature in Surgical Endoscopy
- Vol. 24 (2) , 304-334
Abstract
Perhaps there is no more important issue in the care of surgical patients than the appropriate use of minimally invasive surgery (MIS) for patients with cancer. Important advances in surgical technique have an impact on early perioperative morbidity, length of hospital stay, pain management, and quality of life issues, as clearly proved with MIS. However, for oncology patients, historically, the most important clinical questions have been answered in the context of prospective randomized trials. Important considerations for MIS and cancer have been addressed, such as what are the important immunologic consequences of MIS versus open surgery and what is the role of laparoscopy in the staging of gastrointestinal cancers? This review article discusses many of the key controversies in the minimally invasive treatment of cancer using the pro–con debate format.Keywords
This publication has 188 references indexed in Scilit:
- Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgeryEuropean Journal of Surgical Oncology, 2007
- Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trialEuropean Journal of Surgical Oncology, 2004
- Peritoneal macrophage and blood monocyte functions after open and laparoscopic-assisted cecectomy in ratsSurgical Endoscopy, 2003
- Robotics in General SurgeryArchives of Surgery, 2003
- Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in humansSurgical Endoscopy, 2003
- Vagal-Sparing Esophagectomy: A More Physiologic AlternativeAnnals of Surgery, 2002
- Immune-stimulating effects of low-dose perioperative recombinant granulocyte–macrophage colony-stimulating factor in patients operated on for primary colorectal carcinomaBritish Journal of Surgery, 2001
- Better preservation of immune function after laparoscopic-assisted vs. open bowel resection in a murine modelDiseases of the Colon & Rectum, 1996
- Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative periodSurgery, 1996
- Metabolic and inflammatory responses after open or laparoscopic cholecystectomyBritish Journal of Surgery, 1994